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Background: Pulmonary hypertension (PH) is an important complication to interstitial lung
disease (ILD). The aim of the present study was to investigate the prevalence and impact of
PH on prognosis and exercise capacity in ILD patients.
Methods: 212 ILD patients were screened for PH by echocardiography. Criteria for PH were
either a tricuspid pressure regurgitation gradient >40 mmHg, a tricuspid annular plane systolic
excursion <1.8 cm or right ventricular dilatation. If possible, PH was confirmed by right heart
catheterisation. Pulmonary function tests and 6 min walk tests (6MWT) were performed.
Results: 29 patients (14%) had PH, 16 (8%) had mild and 13 (6%) had severe PH (mean pulmo-
nary artery pressure  35 mmHg). Compared to patients without PH, lung function parameters
were lower in PH patients, a larger proportion had idiopathic pulmonary fibrosis (IPF) (41 vs
21%, p Z 0.006), and the hazard ratio for death was 8.5 (95% CI: 4e17). After correction for
lung function parameters and the presence of IPF, 6MWT was significantly lower in patients
with PH compared to non-PH patients (difference  SEM: 58  22 m, p Z 0.01).
Conclusions: PH occurred in 14% of a cohort of patients with ILD and was associated to IPF and
lower lung function parameters. Mortality was markedly higher in PH patients, and the pres-
ence of PH reduced 6MWT independently of lung function and the presence of IPF. The present
results emphasize the need for intensified treatment of patients with ILD and PH.
ª 2012 Elsevier Ltd. All rights reserved.16 76 92.
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Pulmonary hypertension (PH), defined by a mean pulmo-
nary artery pressure (MPAP) >25 mmHg, is an important
complication to interstitial lung disease (ILD). The gold
standard for diagnosis of PH is right heart catheterisation
(RHC). Echocardiography remains the best non-invasive
screening modality for PH,1 although it is subjected to
inaccuracies.2,3
So far, studies investigating the occurrence of PH in ILD
have focused on lung transplant candidates with idiopathic
pulmonary fibrosis (IPF),4,5 patients with sarcoidosis,6,7 or
scleroderma-related ILD.8,9 The results have shown a great
variation with regard to prevalence, while PH has been
shown to worsen the prognosis in both patients with IPF4
and scleroderma-related ILD.10 However, at tertiary
referral centres, physicians are faced with a broad and
heterogeneous group of patients with ILD, of which several
subtypes are rare.11 At present, very few data describe the
occurrence and impact on prognosis of PH in such pop-
ulations. Furthermore, it is unclear whether PH per se
reduces exercise capacity in ILD, or if it simply reflects
more advanced lung disease.
The aim of the present study was to estimate the prev-
alence, the prognostic effect and the impact of PH on
exercise capacity measured by the 6 min walk test (6MWT)
in ILD patients at a tertiary referral centre in Denmark.
Methods
The study was approved by The Danish Research Ethics
Committee, Region Central Jutland (Issue nr: M-20080219)
and conducted in accordance with the Helsinki Declaration.
Study subjects
Consecutive patients were recruited during 16 months at
a tertiary referral centre for evaluation and treatment of
ILD in Denmark. Potential participants included all preva-
lent and incident cases during the study period with any
subtype of ILD, including patients with sarcoidosis stage
IIeIV. All patients had an echocardiography performed as
part of their initial evaluation.
Inclusion criteria were: age >18 years, written consent
and a diagnosis of ILD according to ATS/ERS guidelines12
based on an overall assessment of high-resolution
computer tomography (HR-CT) scan, lung function tests,
bronchoscopy and biopsy, if available.
Time of inclusion was the date, when echocardiography
was performed.
Diagnoses
Patients were divided into eight diagnostic groups (IPF, Non
specific interstitial pneumonia, desquamative interstitial
pneumonia, hypersensitivity pneumonitis, ILD associated to
rheumatologic disorders, sarcoidosis stage IIeIV, end-stage
fibrosis (manifest end-stage fibrotic changes and inde-
terminable underlying ILD) and other (including patients
with unclassified ILD)).37 patients had a clinical working diagnosis of “unclas-
sified ILD” at the time of inclusion. 21 of these were
reclassified into one of the other diagnostic groups after re-
evaluation of clinical course, HR-CT scans and biopsies. It
was not possible to reclassify 16 patients, who were put in
the category “other” types of ILD.
Use of medication and presence of concomitant cardio-
vascular disease were assessed by interviews and patients’
records.
Echocardiography
The tricuspid regurgitation jet was measured by Doppler
echocardiography in multiple projections, and the tricuspid
pressure regurgitation gradient (TR) was calculated from
the modified Bernoulli equation: 4v2 (v Z peak velocity of
tricuspid regurgitation, m/s). Dimensions of the ventricles
were evaluated from standard projections. The tricuspid
annular plane systolic excursion (TAPSE) was assessed in the
four chamber apical window with the M-mode cursor
through the lateral tricuspid annulus ring. Respiratory
compression of the caval vein was evaluated, and left
ventricular systolic function was assessed by shortening
fraction and wall motion index.
Criteria for a positive screen for PH on echocardiography
were: TR >40 mmHg, right ventricular dilatation or
decreased TAPSE (<1.8 cm).13 If the acoustic windows were
too poor to measure at least one of these parameters,
patients were excluded from the analysis.
RHC
Patients screened positive for PH on echocardiography
were asked to undergo RHC performed with a SwaneGanz
catheter.14 For patients on oxygen therapy, this treatment
was continued during RHC. Otherwise, oxygen was not
used. If patients were formerly diagnosed with PH by RHC,
and signs of PH on echocardiography were still obvious at
inclusion, results from the former RHC were used.
Patient groups
The non-PH group comprised patients screened negative for
PH by echocardiography, and patients who were screened
positive by echocardiography but had an MPAP <25 mmHg
at RHC. Patients with 25  MPAP < 35 mmHg or
a 40 < TR  60 mmHg in the absence of RHC constituted the
mild PH group, and severe PH encompassed patients with
MPAP 35 mmHg or TR >60 mmHg in the absence of RHC.
The PH group included patients with mild or severe PH.
Mortality
Survival status was assessed using the electronic system at
Aarhus University Hospital in which deaths are registered on
a week-to-week basis.
Lung function
Lung function tests included spirometry, body plethys-
mography and determination of diffusion capacity for
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Louisville, Colorado, USA; PFT pro Body, Jaeger, Hoeck-
berg, Germany; Spirometer model 6800, Vitalograph, Ennis,
Ireland) in accordance with the American Thoracic Society
guidelines.15 Predicted values were calculated as recom-
mended by the European Respiratory Society.16
6MWT
6MWT was performed following guidelines from ATS.17 The
tests were conducted on a 30 m track using prescribed
supplemental oxygen. Borg dyspnoea score was recorded
before and immediately after the 6MWT.
Data analysis
Data were analysed in Stata/IC 10 (StataCorp, College
Station, Texas, USA). Survival was analysed with time since
inclusion as time scale. Follow-up was censored eight
months after inclusion of the last patient. Mortality was
estimated by KaplaneMeier curves and differences in
hazard for death (HR) between non-PH and PH patients by
Cox-proportional hazard model. A multivariate cox-hazard
analysis adjusting for age, lung function parameters and IPF
was made. Proportionality was validated by logelog plots.
Parametric data were analysed using Student’s t-test, non-
parametric data by rank sum test, proportions by propor-
tion test, and independent effect of PH on 6MWT was
assessed by multiple linear regression. Logistic regression
was used to calculate odds ratios (OR) for PH.
A p-value below 0.05 was regarded as statistically
significant. Results from normally distributed data are
expressed as means  SEM, non-parametric data as medians
with inter quartile ranges, OR and HR are expressed with
95% confidence intervals (CI).
Results
Patients
268 patients were asked, and 212 accepted to participate.
A comparison was made between the participants and the
56 patients who declined to participate. The 56 non-
participants did not differ from the participants with
respect to age, sex, time from referral, 6MWT (Table 1),
diagnoses (Table S1 in data supplement) or mortality (HR
for death after correction for age was 1.5 (0.6e4.0),
pZ 0.4 in participants vs non-participants). However, non-
participants had higher lung function parameters and were
less likely to receive immunosuppressive treatment and
oxygen (Table 1). Diagnostic categories of participants are
shown in Table 2. Details of rheumatologic disease related
ILD are shown in Tables S2 and S3 in the data supplement.
Echocardiography
Values for TR were obtained in 164 and for TAPSE in 183
patients. In four patients, neither TR, TAPSE nor the right
ventricle could be assessed sufficiently, and the echocar-
diogram was therefore regarded as inconclusive. Thirtypatients were screened positive for PH. In patients
screened negative, there were no significant differences in
lung function, 6MWT or TAPSE between patients with and
without a measurable TR (results shown in Table S4,
supplementary data). Three patients had a TAPSE below
1.8 cm, but no other indices of PH. In one, a TAPSE of
1.7 cm was explained by a former myocardial infarction. In
two, TAPSE was 1.6 and 1.4, but both patients had
a measurable TR below 30 mmHg, and no dilatation of the
right ventricle. These three patients were kept in the non-
PH group.RHC
RHC data from 18 patients screened positive for PH were
obtained. Seven of these had an existing diagnosis of PH
based on RHC (median time from diagnosis to inclusion was
23 (7e36) months). At inclusion, all seven had obvious signs
of PH on echocardiography (TR Z 77  5 mmHg,
TAPSE Z 1.8  0.3 cm, right ventricular dilatation was
present in five). Median time between RHC and inclusion
was within 1.5 (1e2) months of inclusion in the remaining
patients (n Z 11). In one patient, the diagnosis of PH was
discarded (MPAP Z 16 mmHg). One patient had a pulmo-
nary capillary wedge pressure (PCWP) above 15
(PCWPZ 16 mmHg, MPAPZ 44 mmHg, pulmonary vascular
resistance Z 6.5 wood units). Due to the overall clinical
assessment, this patient was kept in the severe PH group.
MPAP in patients with severe PH was 43  2 mmHg, and 62%
of these had right ventricular dilatation as opposed to 6% in
the mild PH group. 12 patients screened positive for PH did
not accept to undergo RHC. These had a mean TR of
53  4 mmHg and TAPSE of 2.1  0.14 cm.Prevalence of PH
Based on echocardiography and RHC, 14% had PH, 8% had
mild PH and 6% had severe PH.Demographics
Compared to patients with no PH, PH patients were older,
time from referral was longer, they were more likely to
receive treatment with immunosuppressives and oxygen
(Table 3) and more likely to have IPF (41 vs 21%, pZ 0.006).
The OR for PH in patients with IPF compared to patients
without IPF was 2.9 (1.03e8.2), pZ 0.043 when Dlco, TLC,
FEV1 and FVC (as % of expected), was corrected for
nZ 199. In patients with mild PH, hypertension and former
myocardial infarction were more frequent (Table S5 in data
supplement).Lung function
In PH patients, Dlco, FEV1 and FVC, were lower than in
patients without PH. Only Dlco was decreased in patients
with severe PH compared to non-PH patients (Table 4). The
median time from inclusion to lung function tests was
0 (0e1) months.
Table 1 Comparison between participants and non-participants.
Demographics Participants
Total n Z 212
n Non-participants
Total n Z 56
n P vs
participants
Age (years) 61  0.9 212 64  1.8 56 0.052
Female (% of patients) 52 212 63 56 0.2
BMI (kg/m2) 27  0.4 212 27  0.7 56 0.7
Time from referral (months) (Median) 11 (0e46) 212 13 (1.5e34) 55 0.7
Immunosuppressive treatment (% of patients) 63 212 34* 56 0.03
Oxygen treatment (% of patients) 16 212 11* 55 0.01
Lung transplant candidates (% of patients) 4 212 0* 56 0.01
Lung function
Dlco (% of expected) 45  1 208 49  2 55 0.1
TLC (% of expected) 69  1 210 75  2* 53 0.01
FVC (% of expected) 71  2 212 83  3* 55 <0.0001
FEV1 (% of expected) 67  1 212 79  3* 55 0.001
Six minute walk test
Distance (metres) 424  8 205 407  18 49 0.4
Comparison of demographic data, lung function and 6 min walk test in participants, and patients who declined to participate in the
study. Total n indicates number of patients in each group. n indicates the number of patients in whom data were available. *Z p < 0.05
vs non-participants. Results are expressed as proportions or means  SEM. Time from referral is expressed as the median with inter
quartile ranges.
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Median follow-up time from inclusion was 1.1 (0.9e1.6)
years. There were 32 deaths, 16 in the PH and 16 in the non-
PH group. Survival curves for non-PH and PH patients are
depicted in Fig. 1. The HR for death after inclusion was 8.5
(4e17), p < 0.001, in the PH group compared to non-PH
patients. After adjusting for age, lung function, IPF and
time from referral in a multivariate cox-hazard analysis, PH
still significantly raised the risk of death (HR Z 7.8
(3.1e20), p < 0.0001) (bivariate cox-regression analysis of
the individual parameters are displayed in Table S7,
supplementary data). There were no statistical significant
differences in survival between IPF and non-IPF patients in
the PH group (HR Z 1.5 (0.5e4.0), p Z 0.440), between
patients who had RHC performed compared to those whoTable 2 Distribution of diagnoses in patients with no, mild and
ILD diagnosis
(% of patients)
All patients
Total
n Z 212
No PH
Total
n Z 179
Mild PH
Total n Z
IPF 23 21 31
NSIP 15 16 6
DIP 6 7 0
Hypersens. pneumonitis 7 8 0
Rheumatologic disease 19 19 25
Sarcoidosis 10 9 13
Endstage 4 3 13*
Other 16 17 13
Distribution of diagnoses in participants with no, mild and severe PH
available in all participants. *Z p < 0.05 vs no PH analysed by propo
(eosinophilic pneumonia (nZ 1) Respiratory bronchiolitis associated-
interstitial pneumonia (n Z 1), alveolar proteinosis (n Z 2), Histioc
exposure (n Z 1), acute interstitial pneumonitis (n Z 1), granulom
Hypersens. pneumonitis: hypersensitivity pneumonitis. *: Proportionhad not (HR Z 2.0 (0.7e6.5), p Z 0.21), or between PH
patients requiring and not requiring oxygen treatment (HR
for death: 2.6 (0.7e9.0), p Z 0.145).
6MWT
Compared to patients without PH, PH patients had shorter
6MWTs (Fig. 2A). PH patients were also more likely to
desaturate below 88%18 (Table 4). Borg dyspnoea score was
significantly higher in mild PH compared to the non-PH
group (Table 4). Corrected for age, gender, BMI, lung
function parameters and the presence of IPF (nZ 199), the
difference in 6MWT between patients without and with PH
was 58  22 m, p Z 0.01. Looking at mild and severe PH
separately, 6MWT in mild-PH patients did not differ signif-
icantly from non-PH patients (33  27 m, p Z 0.2), while
severe PH reduced 6MWT by 89  31 m (p Z 0.005)severe PH.
16
P mild vs
no PH
Severe PH
Total
n Z 13
P Severe vs
No PH
P Severe vs
mild PH
0.3 54* 0.006 0.2
0.3 0 0.11 0.4
0.3 8 0.9 0.3
0.2 0 0.3 e
0.6 15 0.7 0.5
0.7 8 0.7 0.7
0.045 8 0.3 0.7
0.6 8 0.4 0.7
. Total n indicates number of patients in each group. Data were
rtion test. Results are expressed as proportions. Other comprises:
ILD (nZ 2), cryptogenic organizing pneumonia (nZ 1), lymphoid
ytosis X (n Z 2), medically induced ILD (n Z 4), inorganic dust
atous interstitial lung disease (n Z 3), unclassified (n Z 16)).
significantly higher than in patients with no PH.
Table 3 Comparison of demographics in participants with and without PH.
No PH
Total
n Z 179
PH
Total
n Z 29
p (PH vs
No PH)
Age (years) 60  1 65  2* 0.04
Female (% of patients) 51 55 0.7
BMI (kg/m2) 27  0.4 26  1 0.4
Time from referral (months) (Median) 10 (0e39) 39 (8e53)* 0.008
Immunosuppressive
treatment
(% of patients) 58 86* 0.004
Oxygen treatment (% of patients) 9 62* <0.0001
PH specific treatment (% of patients) 0 21* <0.0001
Lung transplant candidates (% of patients) 3 10 0.05
Demographic data for patients included in the study. *: p < 0.05 vs no PH. n indicates number of patients in each group. Total n indicates
number of patients in each group. Data were available in all cases. Results are expressed as proportions or means  SEM. Time from
referral is expressed as the median with inter quartile ranges.
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Dlco from the analysis.
Patients with a 6MWT distance below the 25th percentile
(345 m) had significantly higher OR for PH than patients
with longer 6MWT distance. Correcting for lung function
parameters and IPF, the OR for PH in those with a 6MWT
distance below 345 m was 4.9 (1.68e14.3), p Z 0.004,
n Z 199.
The median time from 6MWT to inclusion was 0 (0e3)
months.
Discussion
The main findings of this study were that 14% of patients
with mixed types of ILD at a tertiary referral centre had PH,
and that 8% and 6% of patients had mild and severe PH,
respectively. Furthermore, the study underlines the
adverse effect of PH on mortality, and shows that PH
independently of lung function impairment restrictsTable 4 Lung function parameters and 6 min walk test in patie
No PH
Total
n Z 179
n PH
Total
n Z 29
n P vs
No PH
Lung function (% of expected)
Dlco 47  1 177 29  3* 28 <0.0001
TLC 70  1 178 65  3 29 0.13
FVC 73  2 179 60  4* 29 0.003
FEV1 69  2 179 55  4* 29 0.001
6 min walk test
Distance (m) 442  9 174 311  20* 28 <0.0001
Saturation < 88%
(% of Pts)
45 173 86* 28 <0.0001
Borg dyspnoea score (Median)
Before 0 (0e1) 169 1 (0e2)* 26 0.007
After 4 (2e7) 169 5.8 (4e7)* 26 0.01
Lung function and 6 min walk test in participants without and with P
number of patients in each group. n indicates number of patients from
or means  SEM. Borg dyspnoea score is expressed as medians with iexercise capacity measured by the 6MWT with a clinically
relevant magnitude.19
Prevalence
In relation to PH, focus is often on IPF patients, and the
present study confirms that IPF may be the most important
ILD when it comes to PH; IPF was markedly over-
represented in the group with severe PH. Also, in
a logistic regression analysis, IPF came out as an indepen-
dent risk factor for PH. This result should, however, be
interpreted with caution due to a limited number of PH
patients for each variable in the analysis. An altered
production of humoral factors such as increased TGF-b20
and endothelin-121 levels and decreased levels of NO22
have been shown to be involved in the pathophysiology of
both IPF and PAH. This may be a plausible explanation for
the association between IPF and PH besides parenchymal
architectural distortion.nts with no, mild and severe PH.
Mild PH
Total
n Z 16
n P vs
No PH
Severe PH
Total
n Z 13
n P vs
No PH
P vs
mild
PH
36  5* 15 0.01 21  3* y 13 <0.0001 0.02
64  4 16 0.2 66  4 13 0.4 0.8
56  5* 16 0.002 66  8 13 0.2 0.3
51  5* 16 0.002 60  7 13 0.13 0.3
343  27* 16 0.001 267  28* 12 <0.0001 0.06
82* 16 0.006 92* 12 0.002 0.4
2 (0e2.5)* 16 0.003 0.25 (0e1) 10 0.50 0.08
6 (3.5e7.5)* 16 0.04 5 (4e7) 10 0.12 0.7
H. *: p < 0.05 vs no PH. y: p < 0.05 vs mild PH. Total n indicates
whom data were available. Results are expressed as proportions
nter quartile range.
Figure 1 Survival KaplaneMeier survival curves in patients
with and without PH. *: p < 0.05 vs no PH.
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nostic groups were represented in the PH group (Table 2).
In former studies, the prevalence of PH in ILD patients
has shown a great variation dependent on the patient
population and the design of the study. For example, in
consecutive sarcoidosis patients, 5.7% had PH based on
echocardiography,6 while a prevalence of 48% was reported
in IPF transplant candidates.5 A number of studies have
investigated lung transplant candidates in whom RHC
measurements are done routinely.4,5,7,23,24 But lung trans-
plant candidates only constitute a small group of patients
at referral centres (less than 4% at our institution), and as
they have particularly advanced lung disease, the preva-
lence of PH may be notably higher than in ILD patients in
general. Furthermore, a retrospective design has been used
in several studies,4,5,7,9,24e27 where patients were included
if data from RHC and/or echocardiography were available.
This approach could also tend to overestimate the preva-
lence of PH, because echocardiography or RHC may have
been performed on suspicion of PH. The present study is
cross-sectional in design, and we aimed to include patients
with ILD, regardless of diagnosis and concomitant cardio-
vascular disease. We find that the approach used in the
present study may reflect the overall prevalence in ILD
better, and gives an impression about the proportion of ILDFigure 2 6MWT. A: Dotplot of 6MWT in patients with no, mild and
by multiple linear regression showing 6MWT distance for men who
function (TLC Z 69, FVC Z 71 and FEV1 Z 67) as a function of difpatients who could potentially benefit from specific treat-
ment of PH, if evidence on this subject emerges. However,
compared to the 212 participants in the study, the 56
patients who declined to participate had equal Dlco and
6MWT, but higher TLC, FEV1, and FVCs. Therefore, it cannot
be excluded that the prevalence estimated in the present
study may also be slightly overestimated.
Prognosis
Prior studies have shown that the presence of PH worsens
the prognosis in selected groups of ILD patients with IPF or
scleroderma-related ILD,4,8,28 including a study by Hamada
et al.28 in which the presence of even mildly elevated MPAP
had an adverse prognostic effect in IPF patients. In accor-
dance, the present study showed a pronounced effect on
the hazard of death after inclusion in patients with PH,
even after correction for age, lung function parameters, IPF
and time from referral, suggesting that PH is an indepen-
dent driver of death. However, the number of deaths in the
present study was small (n Z 32), and consequently, the
multivariate analysis should be interpreted with care.
Nevertheless, the substantial risk of death in approximately
14% of ILD patients at a tertiary referral centre with PH,
calls for an increased effort to improve treatment of ILD-
related PH, either by addressing the underlying diseases
or the pulmonary vasculature more specifically.
6-min walk test
In accordance with other studies,4,29e32 we found a large
difference in 6MWT between patients with and without PH
based on the raw data. Borg dyspnoea score was not
significantly higher in patients with severe PH indicating
that this parameter is not as closely associated to PH as the
6MWT distance. In previous studies, adjustment of the
6MWT for lung function, age, sex and BMI has not been
performed.4,29e34 Even if such factors seem evenly
distributed between groups, they may still contribute to or
mask the effect of PH. The multivariate analysis performed
on our data showed that PH significantly reduced walking
distance independently of lung function and the presence
of IPF, and also that this effect could be attributed to the
patients with severe PH. In patients with severe PH, rightsevere PH. Error bars indicate mean  SEM. B: Model estimated
did not have IPF with average age (61 years), BMI (27), lung
fusion capacity and no, mild or severe PH. *p < 0.05 vs no PH.
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occurred frequently, and this is probably an important
determinant of exercise tolerance. Other studies have
shown that both mild PH and severe PH modifies cardio-
pulmonary exercise testing,33,34 but the magnitude of the
effect of PH is unclear since univariate analyses were used.
The present study is to our knowledge the first to address
the independent effect of mild and severe PH on 6MWT.
In short, our results suggest that mild PH may be
a marker for severe lung impairment, while severe PH is an
independent factor that reduces exercise capacity per se,
speaking in favour of further investigations of specific
treatment in ILD-related PH.
The results also suggest that a 6MWT distance below
345 m is an independent risk factor for PH.
Study limitations
It is a limitation that not all patients were evaluated for PH
by RHC. Echocardiography can produce false positive and
negative results,2 but studies comparing RHC and echo-
cardiography have focused on the echo-estimated systolic
pulmonary artery pressure.2 In the present study reduced
TAPSE,13 right ventricular dilatation and abnormal septal
movement were also determined, which may decrease the
rate of false negatives. PCWP has been shown to be
abnormal in 16% of IPF patients.27 It cannot be excluded
that some of the patients in our study with mild PH that did
not undergo RHC could have predominantly pulmonary
venous hypertension secondary to diastolic dysfunction of
the left ventricle. The higher frequency of hypertension
and previous myocardial infarction observed in this group is
in accordance with that. Also, it cannot be excluded that
some of the patients who did not have RHC undertaken did
not have true PH. To diminish selection bias we decided to
include patients screened positive for PH, although they
refused to undergo RHC. However, it strengthens the study
that all patients with severe PH, except one, had RHC
undertaken. Furthermore, all participants were evaluated
personally by the authors, which is an advantage compared
to previous retrospective studies.
Conclusions
The present study showed that the prevalence of PH was
14% in ILD patients at a tertiary referral centre, and that PH
patients have a substantially worse prognosis than patients
without PH. PH was related to IPF, longer disease duration
and impaired lung function parameters. But even corrected
for lung function parameters and the presence of IPF, PH
limited exercise capacity measured by the 6MWT with
a clinically relevant magnitude, indicating that PH is an
independent worsening factor in ILD patients. The study
thereby underlines the urgent need for new treatment
options in ILD patients with PH.
Supplementary material
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.rmed.2012.
02.015.Conflict of interest statement
None.References
1. Goto K, Arai M, Watanabe A, Hasegawa A, et al. Utility of
echocardiography versus BNP level for the prediction of
pulmonary arterial pressure in patients with pulmonary arterial
hypertension. Int Heart J 2010;5:343e7.
2. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, et al. Echo-
cardiographic assessment of pulmonary hypertension in
patients with advanced lung disease. Am J Respir Crit Care
Med 2003;5:735e40.
3. Nathan SD, Shlobin OA, Barnett SD, Saggar R, et al. Right
ventricular systolic pressure by echocardiography as
a predictor of pulmonary hypertension in idiopathic pulmonary
fibrosis. Respir Med 2008;9:1305e10.
4. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, et al. Prevalence
and outcomes of pulmonary arterial hypertension in advanced
idiopathic pulmonary fibrosis. Chest 2006;3:746e52.
5. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, et al. Pulmonary
hypertension in patients with pulmonary fibrosis awaiting lung
transplant. Eur Respir J 2007;4:715e21.
6. Handa T, Nagai S, Miki S, Fushimi Y, et al. Incidence of
pulmonary hypertension and its clinical relevance in patients
with sarcoidosis. Chest 2006;5:1246e52.
7. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary
hypertension in advanced sarcoidosis: epidemiology and clin-
ical characteristics. Eur Respir J 2005;5:783e8.
8. Chang B, Wigley FM, White B, Wise RA. Scleroderma patients
with combined pulmonary hypertension and interstitial lung
disease. J Rheumatol 2003;11:2398e405.
9. Launay D, Mouthon L, Hachulla E, Pagnoux C, et al. Prevalence
and characteristics of moderate to severe pulmonary hyper-
tension in systemic sclerosis with and without interstitial lung
disease. J Rheumatol 2007;5:1005e11.
10. Le PJ, Humbert M, Mouthon L, Hassoun PM. Systemic sclerosis-
associated pulmonary arterial hypertension. Am J Respir Crit
Care Med 2010;12:1285e93.
11. Dempsey OJ, Kerr KM, Remmen H, Denison AR. How to inves-
tigate a patient with suspected interstitial lung disease. BMJ
2010:c2843.
12. American Thoracic Society/European Respiratory Society
International Multidisciplinary Consensus classification of the
idiopathic interstitial pneumonias. This joint statement of the
American Thoracic Society (ATS), and the European Respira-
tory Society (ERS) was adopted by the ATS board of directors,
June 2001 and by the ERS Executive Committee, June 2001. Am
J Respir Crit Care Med 2002;2:277e304.
13. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, et al.
Tricuspid annular displacement predicts survival in pulmonary
hypertension. Am J Respir Crit Care Med 2006;9:1034e41.
14. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, et al. A
comparison of the acute hemodynamic effects of inhaled nitric
oxide and aerosolized iloprost in primary pulmonary hyper-
tension. German PPH study group. J Am Coll Cardiol 2000;1:
176e82.
15. Rosenberg E. The 1995 update of recommendations for a stan-
dard technique for measuring the single-breath carbon
monoxide diffusing capacity (transfer factor). Am J Respir Crit
Care Med 1996;3(1):827e8.
16. Cotes JE, Chinn DJ, Quanjer PH, Roca J, et al. Standardization
of the measurement of transfer factor (diffusing capacity).
Report working party standardization of lung function tests,
European Community for Steel and Coal. Official Statement of
882 C.U. Andersen et al.the European Respiratory Society. Eur Respir J 1993;(Suppl.):
41e52.
17. ATS statement: guidelines for the six-minute walk test. Am J
Respir Crit Care Med 2002;1:111e7.
18. Lama VN, Flaherty KR, Toews GB, Colby TV, et al. Prognostic
value of desaturation during a 6-minute walk test in idiopathic
interstitial pneumonia. Am J Respir Crit Care Med 2003;9:
1084e90.
19. Du Bois RM, Weycker D, Albera C, Bradford WZ, et al. Six-
minute-walk test in idiopathic pulmonary fibrosis: test valida-
tion and minimal clinically important difference. Am J Respir
Crit Care Med 2011;9:1231e7.
20. Farkas L, Gauldie J, Voelkel NF, Kolb M. Pulmonary hyperten-
sion and idiopathic pulmonary fibrosis: a tale of angiogenesis,
apoptosis, and growth factors. Am J Respir Cell Mol Biol 2011;
1:1e15.
21. Polomis D, Runo JR, Meyer KC. Pulmonary hypertension in
interstitial lung disease. Curr Opin Pulm Med 2008;5:462e9.
22. Hemnes AR, Zaiman A, Champion HC. PDE5A inhibition atten-
uates bleomycin-induced pulmonary fibrosis and pulmonary
hypertension through inhibition of ROS generation and
RhoA/Rho kinase activation. Am J Physiol Lung Cell Mol Physiol
2008;1:L24e33.
23. Todd NW, Lavania S, Park MH, Iacono AT, et al. Variable
prevalence of pulmonary hypertension in patients with
advanced interstitial pneumonia. J Heart Lung Transplant
2010;2:188e94.
24. Whelan TP, Dunitz JM, Kelly RF, Edwards LB, et al. Effect of
preoperative pulmonary artery pressure on early survival after
lung transplantation for idiopathic pulmonary fibrosis. J Heart
Lung Transplant 2005;9:1269e74.
25. Gagermeier J, Dauber J, Yousem S, Gibson K, et al. Abnormal
vascular phenotypes in patients with idiopathic pulmonary
fibrosis and secondary pulmonary hypertension. Chest 2005;
(Suppl. 6):601S.26. Handa T, Nagai S, Miki S, Ueda S, et al. Incidence of pulmonary
hypertension and its clinical relevance in patients with inter-
stitial pneumonias: comparison between idiopathic and
collagen vascular disease associated interstitial pneumonias.
Intern Med 2007;12:831e7.
27. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, et al. Pulmonary
hypertension and pulmonary function testing in idiopathic
pulmonary fibrosis. Chest 2007;3:657e63.
28. Hamada K, Nagai S, Tanaka S, Handa T, et al. Significance of
pulmonary arterial pressure and diffusion capacity of the lung
as prognosticator in patients with idiopathic pulmonary
fibrosis. Chest 2007;3:650e6.
29. Leuchte HH, Neurohr C, Baumgartner R, Holzapfel M, et al.
Brain natriuretic peptide and exercise capacity in lung fibrosis
and pulmonary hypertension. Am J Respir Crit Care Med 2004;
4:360e5.
30. Modrykamien AM, Gudavalli R, McCarthy K, Parambil J.
Echocardiography, 6-minute walk distance, and distance-
saturation product as predictors of pulmonary arterial
hypertension in idiopathic pulmonary fibrosis. Respir Care
2010;5:584e8.
31. Swigris JJ, Olson AL, Shlobin OA, Ahmad S, et al. Heart rate
recovery after six-minute walk test predicts pulmonary
hypertension in patients with idiopathic pulmonary fibrosis.
Respirology 2011;3:439e45.
32. Zisman DA, Karlamangla AS, Ross DJ, Keane MP, et al. High-
resolution chest CT findings do not predict the presence of
pulmonary hypertension in advanced idiopathic pulmonary
fibrosis. Chest 2007;3:773e9.
33. Boutou AK, Pitsiou GG, Trigonis I, Papakosta D, et al. Exercise
capacity in idiopathic pulmonary fibrosis: the effect of
pulmonary hypertension. Respirology 2011;3:451e8.
34. Glaser S, Noga O, Koch B, Opitz CF, et al. Impact of pulmonary
hypertension on gas exchange and exercise capacity in patients
with pulmonary fibrosis. Respir Med 2009;2:317e24.
